Brian B Dow Net Worth

The estimated Net Worth of Brian B Dow is at least $311 Thousand dollars as of 2 March 2015. Brian Dow owns over 2,503 units of Pulse Biosciences Inc stock worth over $310,560 and over the last 13 years Brian sold PLSE stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Brian Dow PLSE stock SEC Form 4 insiders trading

Brian has made over 1 trades of the Pulse Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently Brian bought 2,503 units of PLSE stock worth $12,290 on 2 March 2015.

The largest trade Brian's ever made was buying 2,503 units of Pulse Biosciences Inc stock on 2 March 2015 worth over $12,290. On average, Brian trades about 417 units every 0 days since 2011. As of 2 March 2015 Brian still owns at least 18,119 units of Pulse Biosciences Inc stock.

You can see the complete history of Brian Dow stock trades at the bottom of the page.

What's Brian Dow's mailing address?

Brian's mailing address filed with the SEC is PACIFIC BIOSCIENCES OF CALIFORNIA, INC., 1380 WILLOW ROAD, MENLO PARK, CA, 94025.

Insiders trading at Pulse Biosciences Inc

Over the last 8 years, insiders at Pulse Biosciences Inc have traded over $0 worth of Pulse Biosciences Inc stock and bought 18,070,761 units worth $194,618,110 . The most active insiders traders include Robert W Duggan, Mahkam Zanganeh, and Manmeet Singh Soni. On average, Pulse Biosciences Inc executives and independent directors trade stock every 52 days with the average trade being worth of $6,179,107. The most recent stock trade was executed by Burke Thomas Barrett on 20 May 2024, trading 10,000 units of PLSE stock currently worth $85,600.

What does Pulse Biosciences Inc do?

pulse biosciences, inc. is a clinical stage electroceutical, an electrical energy based therapeutic, company pursuing commercial applications of its proprietary nano-pulse stimulation (nps) technology. nps is a non-thermal, drug-free energy-based technology that can stimulate unique behaviors in cells by applying ultra-short nanosecond (billionths of a second) electrical pulses that affect the cell membrane and intracellular structures. these cell effects influence cell regulation functions and can lead to unique immune system responses. pulse biosciences is investigating a variety of applications for its nps technology that exploits its unique biologic effect, including immuno-oncology and dermatology. pulse biosciences, inc. (plse, nasdaq) corporate headquarters is located in hayward, ca. ~ our mission ~ to build a viable company that designs, produces, and commercializes nano-pulse technology to improve and extend the lives of patients to solve the needs of patients, physicians, and

Complete history of Brian Dow stock trades at Pacific Biosciences of California Inc and Pulse Biosciences Inc

Pulse Biosciences Inc executives and stock owners

Pulse Biosciences Inc executives and other stock owners filed with the SEC include:

• Sandra Gardiner,
  Chief Financial Officer, Executive Vice President - Finance, Treasurer, Secretary
• Darrin Uecker,
  President, Chief Executive Officer, Director
• Darrin R. Uecker,
  Pres, CEO & Director
• Sandra A. Gardiner,
  Exec. VP of Fin. & Admin., CFO, Sec. and Treasurer
• Mitchell Levinson,
  Independent Director
• Edward A. Ebbers,
  Exec. VP & GM of Dermatology
• Edward Ebbers,
  Executive Vice President, General Manager - Dermatology
• Manmeet Soni,
  Independent Director
• Robert Duggan,
  Independent Chairman of the Board
• Kenneth Clark,
  Independent Director
• Mahkam Zanganeh,
  Independent Director
• Mitchell E. Levinson,
  Chief Strategy Officer & Director
• David Danitz,
  Sr. VP of Engineering
• Patty Perla,
  VP of HR
• Dr. Holly Hartman Ph.D., J.D.,
  VP of Bus. Devel. & Corp. Strategy
• Dr. Richard Nuccitelli Ph.D.,
  Chief Science Officer
• Thierry B. Thaure,
  Director
• Robert J. Greenberg,
  Director
• Robert Levande,
  Director
• Brian B Dow,
  CFO & SVP Admin. and Finance
• Thomas J M D Fogarty,
  Director
• Burke Thomas Barrett,
  President and CEO
• Ed Ebbers,
  EVP & GM, Dermatology
• Den Broek Richard Van,
  Director
• Laureen Debuono,
  Director
• Shelley D Spray,
  Director
• Kevin Patrick Danahy,
  Chief Commercial Officer
• Paul A Laviolette,
  Director